Andrew J. Wagner, MD, PhD

Dana-Farber Cancer Institute

Academic Titles

Associate Professor, Medicine, Harvard Medical School

Research Program Affiliation

Member, Developmental Therapeutics

Member, Sarcoma

Research Abstract

Soft tissue sarcomas and bone tumors represent a heterogeneous group of cancers derived from mesenchymal cells. In general, these tumors are often refractory to standard available chemotherapeutic agents. We are interested in identifying critical pathways necessary for these tumors to form and survive, and in developing novel therapeutics that we will test both pre-clinically and in early clinical trials.